FIELD: medicine, psychiatry, pharmacy.
SUBSTANCE: invention proposes a method and pharmaceutical preparation comprising eicosapentaenoic acid in the suitable assimilated formulation for treatment of patients with psychiatric disorder or the central nervous system disorder. The preparation comprises eicosapentaenoic acid taken in the amount at least 90% but preferably at least 95%, and less 5% but preferably less 3% of docosahexaenoic acid of the total amount of fatty acid in this preparation. The preparation is administrated in combination with conventional medicinal agents. Proposed agents provide enhancing effectiveness of treatment that is attained by reducing adverse effect of psychopharmacotherapy used.
EFFECT: improved and valuable medicinal properties of agent.
28 cl, 3 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC COMBINATIONS OF FATTY ACIDS | 2001 |
|
RU2276975C2 |
HUNTINGTON'S DISEASE TREATMENT WITH HELP OF EPA | 2003 |
|
RU2332209C2 |
EICOSAPENTAENOIC ACID (EPA) FOR TREATMENT OF NEUROPSYCHIC ANOREXIA (NA) | 2003 |
|
RU2330653C2 |
THERAPEUTIC AGENTS | 2008 |
|
RU2468025C2 |
METHOD FOR IMPROVING FUNCTIONAL SYNAPTIC CONNECTIVITY | 2013 |
|
RU2667968C2 |
USING ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISEASES, INCREASE NEUROPLASTICITY AND PROMOTE NEUROPROTECTION | 2019 |
|
RU2812786C2 |
ESSENTIAL FATTY ACIDS FOR PREVENTION AND/OR TREATMENT OF DEPRESSION IN PATIENTS SUFFERING FROM CORONARY HEART DISEASE OR CORONARY ARTERY DISEASE | 2005 |
|
RU2387448C2 |
ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
MONOAMINOOXIDASE INHIBITORS, THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2366430C2 |
ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
Authors
Dates
2005-09-20—Published
2000-01-21—Filed